Frank J. Carr

1.2k total citations · 1 hit paper
17 papers, 894 citations indexed

About

Frank J. Carr is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Oncology. According to data from OpenAlex, Frank J. Carr has authored 17 papers receiving a total of 894 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Radiology, Nuclear Medicine and Imaging, 8 papers in Immunology and 4 papers in Oncology. Recurrent topics in Frank J. Carr's work include Monoclonal and Polyclonal Antibodies Research (8 papers), Immune Cell Function and Interaction (3 papers) and Glycosylation and Glycoproteins Research (2 papers). Frank J. Carr is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (8 papers), Immune Cell Function and Interaction (3 papers) and Glycosylation and Glycoproteins Research (2 papers). Frank J. Carr collaborates with scholars based in United Kingdom, United States and India. Frank J. Carr's co-authors include Nino Maida, Philip R. Tempest, William J. Harris, Geraldine Taylor, Julie Furze, Kin-Ming Lo, Stephen D. Gillies, Matthew Baker, Tim D. Jones and Steven A. Williams and has published in prestigious journals such as The Lancet, Blood and Nature Biotechnology.

In The Last Decade

Frank J. Carr

17 papers receiving 789 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Lactic Acid Bacteria: A Literature Survey

2002 521 citations Frank J. Carr, Nino Maida et al. Critical Reviews in Microbiology profile →

Peers

Countries citing papers authored by Frank J. Carr

Since Specialization

Citations

This map shows the geographic impact of Frank J. Carr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank J. Carr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank J. Carr more than expected).

Fields of papers citing papers by Frank J. Carr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank J. Carr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank J. Carr. The network helps show where Frank J. Carr may publish in the future.

Co-authorship network of co-authors of Frank J. Carr

This figure shows the co-authorship network connecting the top 25 collaborators of Frank J. Carr. A scholar is included among the top collaborators of Frank J. Carr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank J. Carr. Frank J. Carr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Microbiology: A Fundamental Introduction 2016 ·Journal of Microbiology & Experimentation ·Frank J. Carr	4
2	Deimmunization of Monoclonal Antibodies 2008 ·Methods in molecular biology ·Tim D. Jones, (unknown), Frank J. Carr, Matthew Baker	38
3	An anti-CD20–IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma 2005 ·Blood ·Stephen D. Gillies, Yan Lan, Steven A. Williams, Frank J. Carr, Stephen J. Forman, Andrew Raubitschek, Kin-Ming Lo	77
4	The Development of a Modified Human IFN-α2b Linked to the Fc Portion of Human IgG1 as a Novel Potential Therapeutic for the Treatment of Hepatitis C Virus Infection 2004 ·Journal of Interferon & Cytokine Research ·Tim D. Jones, (unknown), B.J. Smith, Charles T. Heise, (unknown), Deborah A. Sanders, (unknown), Clive Sweet, Esther Unitt, Graeme Alexander, Kin-Ming Lo, Stephen D. Gillies, Frank J. Carr, Matthew Baker	32
5	A novel CEA vaccine stimulates T cell proliferation, γIFN secretion and CEA specific CTL responses 2004 ·Vaccine ·(unknown), Ian Spendlove, (unknown), (unknown), (unknown), Frank J. Carr, LG Durrant	8
6	Limiting the risk of immunogenicity by identification and removal of T-cell epitopes (DeImmunisation™) 2004 ·Cancer Cell International ·(unknown), Timothy D. Jones, (unknown), (unknown), (unknown), Frank J. Carr	8
7	The Lactic Acid Bacteria: A Literature Survey breakdown → 2002 ·Critical Reviews in Microbiology ·Frank J. Carr, (unknown), Nino Maida	521
8	Human anti-idiotypic antibodies can be good immunogens as they target FC receptors on antigen-presenting cells allowing efficient stimulation of both helper and cytotoxic T-cell responses 2001 ·International Journal of Cancer ·Lindy G. Durrant, (unknown), (unknown), Ian Spendlove, (unknown), Frank J. Carr	19
9	Identification of Residues in the Carboxy-Terminal Domain of Clostridium perfringens α-Toxin (Phospholipase C) Which Are Required for Its Biological Activities 2000 ·Archives of Biochemistry and Biophysics ·Nicola J. Walker, Jane L. Holley, C.E. Naylor, Marietta Flores-Dı́az, Alberto Alape‐Girón, (unknown), Frank J. Carr, Monica Thelestam, (unknown), David S. Moss, Ajit K. Basak, Julie Ann Miller, Richard W. Titball	14
10	A Humanized Antibody against Human Cytomegalovirus (CMV) gpUL75 (gH) for Prophylaxis or Treatment of CMV Infections 1997 ·The Journal of Infectious Diseases ·(unknown), (unknown), Jane E. Grundy, Andrew Turner, (unknown), John R. Adair, Patricia M. White, Frank J. Carr, William J. Harris	13
11	Identification of framework residues required to restore antigen binding during reshaping of a monoclonal antibody against the glycoprotein gB of human cytomegalovirus 1995 ·International Journal of Biological Macromolecules ·Philip R. Tempest, Piran C. L. White, (unknown), Frank J. Carr, William J. Harris	16
12	A Humanized Anti-Tumor Necrosis Factor-α Monoclonal Antibody That Acts as a Partial, Competitive Antagonist of the Template Antibody 1994 ·Hybridoma ·Philip R. Tempest, (unknown), (unknown), Frank J. Carr, (unknown), (unknown), Fabrizio Marcucci	2
13	Efficient generation of a reshaped human mAb specific for the α toxin of Clostridium perfringens 1994 ·Protein Engineering Design and Selection ·Philip R. Tempest, Patricia M. White, E. Diane Williamson, Richard W. Titball, D. C. Kelly, Graham J. Kemp, Peter Gray, (unknown), Frank J. Carr, William J. Harris	3
14	Idiotope determining regions of a mouse monoclonal antibody and its humanized versions 1994 ·Journal of Molecular Biology ·Angelo Corti, (unknown), Philip R. Tempest, Frank J. Carr, Fabrizio Marcucci	8
15	Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection in Vivo 1991 ·Nature Biotechnology ·Philip R. Tempest, (unknown), (unknown), Geraldine Taylor, Julie Furze, Frank J. Carr, William J. Harris	126
16	Urban Statistics and Their Treatment and Use for Decision-Makers 1970 ·Management Science ·Frank J. Carr	3
17	REMPLOY 1954 ·The Lancet ·Frank J. Carr	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact